MIGNONE ROBERTO 4

What Happened Roberto Mignone, a director of Guardant Health (GH), executed a conversion/exercise of a derivative instrument on January 21, 2026 that resulted in the acquisition of 264 shares at a reported price of $0. The same filing also records a simultaneous disposition of 264 derivative-based shares at $0. The filing indicates these transactions relate to vested restricted stock units rather than an open-market buy or sale.

Key Details

• Transaction date: 2026-01-21 (reported on Form 4 filed 2026-01-22) — filing appears timely.
• Transaction code: M (exercise or conversion of derivative).
• Shares acquired: 264 at $0.00 (total cash paid reported = $0).
• Shares disposed: 264 at $0.00 (reported as derivative disposition).
• Shares owned after the transaction: not specified in the filing.
• Footnotes: F1 notes the RSU grant (11/08/2024) vests over four years (25% at one year, remainder monthly over three years); F2 not applicable for RSUs.
• No 10b5-1 plan, tax-withholding sale, or open-market sale is specified in the filing.

Context This was a conversion/settlement of derivative awards (restricted stock units) rather than a market purchase or sale. Because the reported per-share price is $0 and no cash sale is shown, the transaction likely reflects vesting/settlement mechanics rather than an expression of buy/sell sentiment; the filing itself does not state a reason for the $0 disposition (e.g., tax withholding) so no assumptions are made. Purchases are generally more informative about insider sentiment; this filing documents routine equity award settlement.